Procella Therapeutics AB

City:

Tullinge

Country:

Sweden

Published Applications:

Last publication date:

2022-04-14

Patent Grants:

Last grant date:

2025-09-02

Top Inventors for applications by Procella Therapeutics AB

These are the the leading inventors for applications assigned to Procella Therapeutics AB:

Kenneth R. Chien 8 Cambridge, MA United States
Chuen Yan LEUNG 6 Stockholm, Sweden
Jonathan CLARKE 6 Stockholm, Sweden
Kylie FOO 2 Stockholm, Sweden

Makoto SAHARA 2 Stockholm, Sweden
Federica SANTORO 2 Stockholm, Sweden
Jiejia XU 2 Solna, Sweden
Miia LEHTINEN 2 Tuusula, Finland

Xiaojun Lance LIAN 1 University Park, PA United States
Xiaojun LIAN 1 Solna, Sweden

Recent patent applications by Procella Therapeutics AB

Procella Therapeutics AB based in Tullinge, SE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-04-14 ✅ Patent 12,404,488 granted on 2025-09-02

US20220112458A1

Chemistry; metallurgy

USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS

#2 | 2020-08-27 ✅ Patent 11,725,244 granted on 2023-08-15

US20200270685A1

Chemistry; metallurgy

Genetic markers for engraftment of human cardiac ventricular progenitor cells

#3 | 2020-05-07 ✅ Patent 11,401,508 granted on 2022-08-02

US20200140819A1

Chemistry; metallurgy

Methods for isolating human cardiac ventricular progenitor cells

#4 | 2019-02-28 ✅ Patent 11,186,820 granted on 2021-11-30

US20190062696A1

Chemistry; metallurgy

Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cells

#5 | 2018-05-31 ✅ Patent 10,508,263 granted on 2019-12-17

US20180148691A1

Chemistry; metallurgy

Methods for isolating human cardiac ventricular progenitor cells

#6 | 2017-08-24 ✅ Patent 10,612,094 granted on 2020-04-07

US20170240964A1

Chemistry; metallurgy

Genetic markers for engraftment of human cardiac ventricular progenitor cells

#7 | 2016-04-21 ✅ Patent 10,596,200 granted on 2020-03-24

US20160108363A1

Chemistry; metallurgy

Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells

#8 | 2016-02-25 ✅ Patent 10,597,637 granted on 2020-03-24

US20160053229A1

Chemistry; metallurgy

Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells

Also check out Procella Therapeutics AB's (Tullinge, Sweden) applicant profile with 8 patent applications submitted.

AssigneeID:

383589 ⎘